You Are Now Leaving

The website you are linking to is neither owned nor controlled by Astellas. Astellas is not responsible for the content or services on this site.



Step 1: Select language(s)

English Arabic Cantonese
French Creole Korean Mandarin
Russian Spanish Vietnamese

Step 2: Customize document(s) (OPTIONAL)

Step 1: Customize document (OPTIONAL)

If you would like to add your facility's name, address, and/or logo to this PDF, please complete the fields below.

Step 4: Download PDF(s)

Step 3: Download PDF

Download PDF(s)
Download PDF(s)
Download PDF(s)
Download PDF(s)
This information is intended for US healthcare professionals only.
Text Size Adjustment

The Clinical Value of MPI

The Clinical Value of MPI

The Diagnostic and Prognostic Value of MPI

Considerations for the MPI Modalities and Your Patient

When a patient’s pretest probability of CAD is intermediate to high, myocardial perfusion imaging (MPI) may be an appropriate modality for risk stratification and patient management.1

Either SPECT or positron emission tomography (PET) MPI can be used to identify ischemia and prior infarction, risk stratify patients with known or suspected CAD, and guide clinical management decisions regarding medical therapy or revascularization.2 There are some differences between these modalities that should be considered when selecting the right modality for the right patient.

Astellas offers information and educational resources to help support shared clinical decision-making, collaborative care, and appropriate testing referrals.

Noninvasive Modalities for the Assessment of Coronary Artery Disease

For more information on noninvasive cardiac testing modalities, download this booklet or explore a more complete library of resources on


1. Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease. J Am Coll Cardiol 2012;60(24):e44-164. Erratum in: J Am Coll Cardiol 2014;63(15):1588-90. 2. Udelson JE, Dilsizian V, Bonow RO. Nuclear cardiology. In: Zipes DP, Libby P, Bonow RO, Mann DL, Tomaselli GF, Braunwald E, eds. Braunwald’s Heart Disease. 11th ed. Philadelphia, PA: Elsevier Saunders, 2019:261-300. 3. Driessen RS, Raijmakers PG, Stuijfzand WJ, Knaapen P. Myocardial perfusion imaging with PET. Int J Cardiovasc Imaging 2017;33(7):1021-31. 4. Bateman TM, Heller GV, McGhie AI, et al. Diagnostic accuracy of rest/stress ECG-gated Rb-82 myocardial perfusion PET: comparison with ECG-gated Tc-99m sestamibi SPECT. J Nucl Cardiol 2006;13(1):24-33. 5. Henzlova MJ, Duvall WL, Einstein AJ, Travin MI, Verberne HJ. ASNC imaging guidelines for SPECT nuclear cardiology procedures: stress, protocols, and tracers. J Nucl Cardiol 2016;23(3):606-39. Erratum in: J Nucl Cardiol 2016;23(3):640-2. 6. DePuey EG, Mahmarian JJ, Miller TD, et al. Patient-centered imaging. J Nucl Cardiol 2012;19(2):185-215. Erratum in: J Nucl Cardiol 2012;19(3):633. 7. Dorbala S, Ananthasubramaniam K, Armstrong IS, et al. Single Photon Emission Computed Tomography (SPECT) myocardial perfusion imaging guidelines: instrumentation, acquisition, processing, and interpretation. J Nucl Cardiol 2018;25(5):1784-846.